Literature DB >> 10480370

The frequency of lysosomal storage diseases in The Netherlands.

B J Poorthuis1, R A Wevers, W J Kleijer, J E Groener, J G de Jong, S van Weely, K E Niezen-Koning, O P van Diggelen.   

Abstract

We have calculated the relative frequency and the birth prevalence of lysosomal storage diseases (LSDs) in The Netherlands based on all 963 enzymatically confirmed cases diagnosed during the period 1970-1996. The combined birth prevalence for all LSDs is 14 per 100,000 live births. Glycogenosis type II is the most frequent LSD with a birth prevalence of 2.0 per 100,000 live births, representing 17% of all diagnosed cases. Within the group of lipidoses, metachromatic leukodystrophy (MLD) is the most frequent LSD. MLD was diagnosed in 24% of lipidoses and the calculated birth prevalence was 1.42 per 100,000 for all types combined. Krabbe disease, diagnosed in 17% of cases, also belongs to the more frequent lipid storage diseases in The Netherlands with a birth prevalence of 1.35 per 100,000. The birth prevalence of Gaucher disease, commonly regarded as the most frequent lipid storage disease is 1.16 per 100,000 for all types combined. The combined birth prevalence for all lipid storage diseases is 6.2 per 100,000 live births. Within the group of mucopolysaccharidoses (MPSs), MPS I has the highest calculated birth prevalence of 1.19 per 100,000 (25% of all cases of MPS diagnosed), which is slightly more frequent than MPS IIIA with an estimated birth prevalence of 1.16 per 100,000. As a group, MPS III comprises 47% of all MPS cases diagnosed and the combined birth prevalence is 1.89 per 100,000 live births. The birth prevalence of MPS II is 0.67 per 100,000 (1.30 per 100,000 male live births). All other MPSs are rare. The combined birth prevalence for all MPSs is 4.5 per 100,000 live births. Mucolipidoses and oligosaccharidoses are very rare with birth prevalences between 0.04 and 0.20 for individual diseases. Only 49 cases were diagnosed between 1970 and 1996. Their combined birth prevalence is 1.0 per 100,000 live births.

Entities:  

Mesh:

Year:  1999        PMID: 10480370     DOI: 10.1007/s004399900075

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  205 in total

Review 1.  Fabry disease, enzyme replacement therapy and the significance of antibody responses.

Authors:  Patrick B Deegan
Journal:  J Inherit Metab Dis       Date:  2011-10-25       Impact factor: 4.982

2.  Screening for Attenuated Forms of Mucopolysaccharidoses in Patients with Osteoarticular Problems of Unknown Etiology.

Authors:  Thabata Caroline da Rocha Siqueira; Carolina Fischinger Moura de Souza; Paulo Lompa; Mercedes Picarelli; Ilóite Scheibel; Fernanda Bender; Régis Guidobono; Maira Graeff Burin; Roberto Giugliani
Journal:  JIMD Rep       Date:  2015-08-28

3.  Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease.

Authors:  Miroslav Vujasinovic; Bojan Tepes; Bojan Vujkovac; Andreja Cokan Vujkovac; Martin Tretjak; Vesna Korat
Journal:  Wien Klin Wochenschr       Date:  2015-04-03       Impact factor: 1.704

4.  Rheumatologic aspects of lysosomal storage diseases.

Authors:  Bernhard Manger; Eugen Mengel; Roland M Schaefer
Journal:  Clin Rheumatol       Date:  2006-05-06       Impact factor: 2.980

Review 5.  Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.

Authors:  Carla E M Hollak; Johannes M F G Aerts; Ségolène Aymé; Jeremy Manuel
Journal:  Orphanet J Rare Dis       Date:  2011-04-16       Impact factor: 4.123

6.  Cumulative incidence rates of the mucopolysaccharidoses in Germany.

Authors:  F Baehner; C Schmiedeskamp; F Krummenauer; E Miebach; M Bajbouj; C Whybra; A Kohlschütter; C Kampmann; M Beck
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

7.  Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA.

Authors:  Robin K Rumsey; Kyle Rudser; Kathleen Delaney; Michael Potegal; Chester B Whitley; Elsa Shapiro
Journal:  J Pediatr       Date:  2014-02-25       Impact factor: 4.406

8.  A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.

Authors:  N M Ellinwood; P Wang; T Skeen; N J H Sharp; M Cesta; S Decker; N J Edwards; I Bublot; J N Thompson; W Bush; E Hardam; M E Haskins; U Giger
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

9.  Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Sung Yoon Cho; Rimm Huh; Mi Sun Chang; Jieun Lee; Younghee Kwun; Se Hyun Maeng; Su Jin Kim; Young Bae Sohn; Sung Won Park; Eun-Kyung Kwon; Sun Ju Han; Jooyoun Jung; Dong-Kyu Jin
Journal:  J Korean Med Sci       Date:  2014-01-28       Impact factor: 2.153

10.  A Clinically Severe Variant of β-Mannosidosis, Presenting with Neonatal Onset Epilepsy with Subsequent Evolution of Hydrocephalus.

Authors:  A Broomfield; R Gunny; I Ali; A Vellodi; P Prabhakar
Journal:  JIMD Rep       Date:  2013-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.